Company intelligence / Profile preview

Phanes Therapeutics, Inc.

San Diego, California, United Statesphanesthera.com ↗

Ownership: Private
Employees: ~27
Development stage: Preclinical

Overview

Currently conducting three Phase I clinical trials: MORNINGSTAR study with PT199 (mAb program), TWINPEAK study with PT886, and SKYBRIDGE study with PT217. PT886 and PT217 have been granted orphan drug designation and Fast Track designation by the FDA. PT217 received Fast Track designation for neuroendocrine prostate cancer (NEPC) and extensive-stage small cell lung cancer (ES-SCLC).

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodies
Industry: Biotech

Drug pipeline

10 assets

peluntamig

9 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Phanes Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phanes Therapeutics, Inc..

Explore the full profile